NEW YORK, Jan. 30 (GenomeWeb News) - BioTrove and RxGen PrimaTox are working jointly to provide gene expression and SNP assays for primates and humans, BioTrove said today.
Under the deal, RxP will provide its tox-optimum assays exclusively to BioTrove, either as stand-alone products or as a service. BioTrove will manufacture the assays to RxP's specifications, using its OpenArray platform.
Financial details were not disclosed.
As GenomeWeb News reported last week, RxGen PrimaTox is a wholly owned subsidiary of RxGen focused on drug-safety products and services. It is also building a primate-based molecular toxicology database to be available on a subscription basis.